Ra-223 dichloride management in a Nuclear Medicine Unit: experience of a referral institution
Open Access
- 1 January 2017
- journal article
- Published by Heighten Science Publications Corporation in Journal of Radiology and Oncology
- Vol. 1 (3), 069-078
- https://doi.org/10.29328/journal.jro.1001010
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2013
- Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate CancerInternational Journal of Molecular Sciences, 2013
- Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapyUrologic Oncology, 2012
- A bone marrow toxicity model for223Ra alpha-emitter radiopharmaceutical therapyPhysics in Medicine & Biology, 2012
- Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006Prostate Cancer and Prostatic Diseases, 2011
- High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?Clinical Cancer Research, 2006
- First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal MetastasesClinical Cancer Research, 2005
- Targeted α-therapy for control of micrometastatic prostate cancerExpert Review of Anticancer Therapy, 2004